Search Results - cb3cxx

6 Results

Sort By:

Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor To Enhance Immune Response and Inflammation

Local inflammation processes are crucially important in the host defense against pathogens and for successful immunization because proinflammatory cytokines are necessary for initiation and propagation of an immune response. However, normal inflammatory responses are eventually terminated by physiological termination mechanisms, thereby limiting the...

Published: 7/25/2024 | Inventor(s): Akio Ohta, Michail Sitkovsky

Keywords(s): 2IXXXX, 2JXXXX, CB3CXX, CB6XXX, Controlling, DC1XXX, IA3XXX, Inflammation, Listed LPM Thalhammer-Reyero as of 4/15/2015, Method, Patent Category - Chemistry, Post LPM Assignment Set 20150420, Pre LPM working set 20150418

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Therapeutics, Application > Vaccines

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 7/25/2024 | Inventor(s): Christopher Bachran, Stephen Leppla

Keywords(s): Anthrax, AnthraxToxins, CB1BXX, CB1XXX, CB3CXX, CB3XXX, CBXXXX, CXXXXX, fusion proteins, Patent Category - Biotechnology, THERAPY, toxin, tumor

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath

Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases

A3 Adenosine Receptor Agonists to Treat Chemotherapy-induced Peripheral Neuropathy

This invention claims species-independent agonists of A3AR, specifically (N)-methanocarba adenine nucleosides and related pharmaceutical compositions. The A3 adenosine receptor (A3AR) subtype has been linked with helping protect the heart from ischemia, controlling inflammation, and regulating cell proliferation. Agonists of the human A3AR subtype...

Published: 4/8/2024 | Inventor(s): Dilip Tosh, Kenneth Jacobson

Keywords(s): 2-Arylethynyl, A3, ADENOSINE, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Design, N-Methanocarba, Nucleosides, Receptor-Selective, Structure-based

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics

Pyruvate Kinase M2 Activators for the Treatment of Cancer

NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage...

Published: 7/25/2024 | Inventor(s): Min Shen, Craig Thomas, Douglas Auld, Matthew Boxer

Keywords(s): [1, [b], 2, 2-oxo-1, 3, 3-oxo-3, 4], 4-dihydroquinoline-2H-benzo, 4-tetrahydroquinoline-6-sulfonamides, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Human, Kinase, MOLECULE, Oxazine-7-sulfonamides, Patent Category - Chemistry, PYRUVATE, Small, Substituted

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology

Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia

Published: 7/25/2024 | Inventor(s): Craig Thomas

Keywords(s): 3-@hydroxyacyl-coa dehydrogenase deficiency, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, HAD deficiency, HIS deficiency, Histidinemia, Human, Kinase, MOLECULE, Patent Category - Chemistry, PYRUVATE, Small

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology